Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study

• Published in: Respiratory research Vol. 22; no. 1; pp. 34 - 9
• Main Authors: Klose, Hans, Chin, Kelly M., Ewert, Ralf, Gall, Henning, Parambil, Joseph, Poch, David, Seyfarth, Hans-Jürgen, Axelsen, Lene N., Hsu Schmitz, Shu-Fang, Stein, Claudia, Preston, Ioana R.
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 03.02.2021; BioMed Central; BMC
• Subjects: Adverse events; Blood pressure; Dosage; Drug therapy; Exposure; Hypertension; Intravenous; Intravenous administration; Metabolites; Oral administration; Patient outcomes; Patients; Pharmacokinetics; Pharmacology; Plasma; Pulmonary arterial hypertension; Pulmonary hypertension; Safety; Selexipag; Switching; Treatment interruptions; Germany; United States > US; Pulmonary arterial hypertension; Pharmacokinetics; Intravenous; Treatment interruptions; Selexipag

The oral IP receptor agonist selexipag is approved for the long-term treatment of pulmonary arterial hypertension (PAH). Treatment interruptions should be avoided due to the progressive nature of the disease. An intravenous (IV) formulation of selexipag was developed to provide a treatment option fo...